**Appendix 2. Baseline Patient Characteristics Stratified by Indication and Treatment History: Patients who Completed the Study**

|  |  |
| --- | --- |
| Characteristic | Indication; no. (%) of patientsa |
| Adult focal spasticity | Blepharospasm | Cerebral palsy | Cervical dystonia | Hemifacial spasm | Hyperhidrosis |
| naïve | maint | naïve | maint | naïve | maint | naïve | maint | naïve | maint | naïve | maint |
|  | (N=46) | (N=122) | (N=10) | (N=38) | (N=0) | (N=3) | (N=12) | (N=126) | (N=23) | (N=53) | (N=8) | (N=14) |
| Age*years, mean* ±*SD* | 55±17 | 54±16 | 66±11 | 63±12 |  - | 15±1 | 60±13 | 57±11 | 64±11 | 66±11 | 36±10 | 36±8 |
| *Diff (95%CI)b* | 0.9 (-5.0, 6.7) | 2.3 (-6.4, 10.9) |  - | -2.8 (-5.8, 11.5) | -2.1 (-7.6, 3.3) | -0.1 (-9.3, 9.1) |
| Gender*Female**Male* | 25 (54)21 (46) | 76 (62)46 (38) | 6 (60)4 (40) | 21 (55)17 (45) | 0 (0)0 (0) | 1 (33)2 (67) | 9 (75)3 (25) | 96 (76)30 (24) | 16 (70)7 (30) | 38 (72)15 (28) | 6 (75)2 (25) | 12 (86)2 (14) |
| Race*White/Caucasian**Otherc* | 42 (91)4 (9) | 110 (90)12 (10) | 9 (90)1 (10) | 37 (97)1 (3) | 0 (0)0 (0) | 3 (100)0 (0) | 12 (100)0 (0) | 124 (98)2 (2) | 18 (78)5 (22) | 50 (94)3 (6) | 8 (100)0 (0) | 13 (93)1 (7) |
| Employment*Full-time**Part-time**Retired**Self-Employed**Unemployed**Other* | 3 (7)2 (4)19 (41)2 (4)15 (33)5 (11) | 8 (7)10 (8)35 (29)3 (2)47 (38)19 (16) | 2 (20)1 (10)7 (70)0 (0)0 (0)0 (0) | 9 (24)5 (13)21 (55)0 (0)1 (3)2 (5) | 0 (0)0 (0)0 (0)0 (0)0 (0)0 (0) | 0 (0)0 (0)0 (0)0 (0)0 (0)3 (100) | 3 (25)1 (8)4 (33)0 (0)2 (17)2 (17) | 42 (33)11 (9)40 (32)8 (6)22 (18)3 (2) | 3 (13)2 (9)15 (65)2 (9)1 (4)0 (0) | 11 (21)3 (6)32 (60)0 (0)2 (4)5 (9) | 6 (75)0 (0)0 (0)0 (0)1 (13)1 (12) | 8 (57)2 (14)0 (0)2 (14)0 (0)2 (15) |
| Time since diagnosis*months, median (range)* | 35(2-736) | 76(5-786) | 10(4-44) | 72(20-261) | -- | 181(179-196) | 10(5-119) | 87(8-589) | 12(3-201) | 93(8-507) | 52(5-376) | 41(11-282) |
| Time since first treatment prior to study entryd*months, mean (SD)* | NA | 31.7±28.2 | NA | 77.5±59.5 | NA | 47.0±43.3 | NA | 73.6±58.8 | NA | 77.0±59.3 | NA | 23.8±17.8 |
| Number of injections per yearc*number, mean (SD)* | NA | 3.4±0.9 | NA | 3.6±1.0 | NA | 2.0±1.0 | NA | 3.5±0.9 | NA | 3.5±0.7 | NA | 1.8±0.6 |

CI=confidence interval, Diff=difference, maint=maintenance; SD=standard deviation

a Unless otherwise indicated

b Difference calculated for naïve minus maintenance groups, for means

c Includes the following which were each ≤5% of the population: Aboriginal, Arab/West Asian, Black, Chinese, Filipino, Japanese, Korean, Latin American, South Asian, South East Asian, and/or those categorized as “other”, except for the cerebral palsy cohort where South Asian accounted for 9% (n=2) of the maintenance population

d OnabotulinumtoxinA treatment characteristics prior to entering study; only applicable to maintenance patients